Lumos Diagnostics Holdings Ltd. · ASX:LDX
Lumos Diagnostics — FY2025 Earnings Presentation
35 slides from Lumos Diagnostics's earnings presentation, Sep 2, 2025
Slide 1: FY25 Results - Investor Briefing Presentation
ASX ANNOUNCEMENT FY25 Results - Investor Briefing Presentation For personal use only MELBOURNE, Australia (2 September 2025) – Lumos Diagnostics Holdings Ltd (ASX:LDX, “Lumos” or the “Company”) a leader in rapid, point-of-care diagnostic technologies, is pleased to release a copy of the pr esentatio
Slide 2: Forward-Looking Statements
Forward-Looking Statements This announcement contains forward-looking statements, including references to forecasts. Forward- looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are be
Slide 3: FY25 Results Investor Briefing
For personal use only Lumos Diagnostics Holdings Limited FY25 Results Investor Briefing 3 September 2025 Financial information is shown in USD unless otherwise stated. www.lumosdiagnostics.com © Lumos Diagnostics . All rights reserved. 1
Slide 4: Disclaimer and Important Information
Disclaimer and Important Information This presentation (Presentation) has been prepared solely for informational purposes by Lumos Diagnostics Holdings Limited representation, as to the past, present or the future. Past performance is not necessarily a guide to future likelihood of For personal use
Slide 5: Lumos develops, manufactures and distributes diagnostic products
For personal use only Lumos develops, manufactures and distributes innovative diagnostic products – delivering actionable information, in real time, at the point-of-care. © Lumos Diagnostics , all rights reserved 3
Slide 6: Company Snapshot
Company Snapshot Issued Capital Share Price (AUD) & Volume For personal use only Shares 753.5m Options / Performance Rights 174.0m Market Capitalization (AUD) Share price1 A$0.125 Market value A$94.2m Pro-forma Cash (30 June 2025 – in AUD)2 A$3.0m Enterprise value A$91.2m Substantial Shareholders Te
Slide 7: Key FY25 Highlights
For personal use only Key FY25 Highlights
Slide 8: Key Highlights From FY25 & Post Reporting Date
Key Highlights From FY25 & Post Reporting Date For personal use only $ Revenue of US$12.4 million for the year, up Major distribution agreement signed with FebriDx - CLIA Waiver study completed, 11% compared to prior year (FY24 - US$11.1 PHASE Scientific for the U.S. market - for exceeding performan
Slide 9: FY25 Financials
For personal use only FY25 Financials
Slide 10: Profit & Loss Summary – FY25
Profit & Loss Summary – FY25 Strong revenue growth and EBITDA improvement For personal use only (US$ in thousands) Year ended 30 June FY25 FY24 % Change Revenue Services revenue 10,577 9,885 +7% • Total revenue $12.4m (+11%) • Services revenue $10.6m (+7%) - positive impact from Hologic Products rev
Slide 11: Balance Sheet Summary – FY25
Balance Sheet Summary – FY25 Improved net current asset position (US$ in thousands) For personal use only Period ending 30 Jun 2025 30 Jun 2024 +/- Assets • Cash as at 30 June was $2.0m Cash 1,956 6,479 -4,523 Inventories 521 784 -263 • Inventory mainly raw materials and finished goods for FebriDx.
Slide 12: Cashflow Summary – FY25
Cashflow Summary – FY25 Closing cash $2.0m - well supported capital raise (US$ in thousands) • Receipts from customers at $6.4m, is lower than revenue reported For personal use only Year ended 30 Jun FY25 FY24 +/- mainly due to recognising revenue on Hologic IP agreement (cash of Receipts from custo
Slide 13: Binding term sheet for loan facility
Binding term sheet for loan facility – Announced 17 July 2025 For personal use only Binding term sheet signed with supportive major shareholders Tenmile and Ryder Capital Funding of up to A$5.0 million, as required, on 12-month term, with option to extend by a further 12-months The loan is designed
Slide 14: Products Division
For personal use only Products Division
Slide 15: About FebriDx: Lumos' First-of-its-kind Point Of Care Test
About FebriDx®: Lumos’ First-of-its-kind Point Of Care Test FebriDx® is an aid for healthcare providers to improve patient care and antibiotic stewardship For personal use only The majority of acute respiratory infections are caused by viruses and do not require antibiotics, yet antibiotics are pres
Slide 16: FebriDx: A Simple And Unique Test For Microbial Infection
FebriDx® A Simple And Unique Test For Microbial Infection FebriDx® can rapidly identify patients who have a microbial infection1 and, if positive, determine if that infection is caused by a viral or bacterial pathogen after 10 minutes For personal use only FebriDx® Test Procedure and Interpretation
Slide 17: FebriDx Addresses A Major Need: Antibiotic Overprescription
FebriDx® Addresses A Major Need: Antibiotic Overprescription ANTIBIOTICS PRESCRIBED (U.S.) ANTIBIOTICS PRESCRIBED IN THE U.S. BY TYPE For personal use only Common cold Sinusitis Other infections Bronchitis Sore throat Ear infection 211M antibiotic prescriptions issued in outpatient settings each yea
Slide 18: FebriDx Journey To Transform The Practice Of Medicine
FebriDx® Journey To Transform The Practice Of Medicine Recent achievements forming the critical commercialisation backbone for FebriDx® For personal use only Q1 CY2026 Phase Scientific $5.0m pre-paid purchase order Q1 CY2026 triggered FDA grant of CLIA waived Oct 2025 anticipated Sep 2025 Pediatric
Slide 19: PHASE Scientific Partnership
PHASE Scientific Partnership A pivotal agreement - one of the largest distribution deals of its type to be done by an ASX-listed point of care diagnostics company For personal use only Summary of anticipated payments (US$) Exclusive U.S. distribution agreement signed for Payment With CLIA FebriDx® w
Slide 20: FebriDx CLIA Waiver Study Update
FebriDx® CLIA Waiver Study Update BARDA partnership agreement announced in October 2024 • BARDA partnership agreement: non-dilutive funding up to US$8.3 million For personal use only committed to support CLIA waiver and pediatric studies (US$3.0m for CLIA waiver study and US$5.3m for pediatric study
Slide 21: FebriDx US CLIA Waived Market Opportunity > US$1 Billion
FebriDx® US CLIA Waived Market Opportunity > US$1 Billion A CLIA waiver allows facilities such as physician offices or urgent care centers to perform simple, low-risk tests without the full regulatory requirements of higher-complexity labs, provided they follow test instructions and maintain a CLIA
Slide 22: Lumos Partners with BARDA to Commence FebriDx Pediatric Study
Lumos Partners with BARDA to Commence FebriDx® Pediatric Study • FebriDx® is currently FDA-cleared for use in patients aged 12- For personal use only 64 years presenting to urgent care or emergency care settings for evaluation of acute respiratory infection • Lumos to commence FebriDx® pediatric stu
Slide 23: The path to commercial adoption
The path to commercial adoption For personal use only Clinical Economic Operational Benefit Benefit Efficiency Only test that distinguishes Reimbursed under PLA code Easily integrated alongside between bacterial and at $41.38 per test, creating COVID/Flu combo tests without non-bacterial acute respi
Slide 24: Reimbursement 101: Path Of A New PLA Code
Reimbursement 101: Path Of A New PLA Code • 0442U: PLA Code assigned for FebriDx Code Creation • Provides a unique billing pathway and claims tracking For personal use only • CMS established rate on CLFS (Clinical Lab Fee Schedule) for FebriDx at US$41.38 CMS Payment Rate • Serves as the initial rei
Slide 25: The IVD Value Chain And Economic Flow
The IVD Value Chain And Economic Flow • Manufacturers o Role: R&D and production of IVD products For personal use only o Gross Margin: ~60% o Margin Growth: Target 80% driven by volume, supplier price reduction, and manufacturing automation • Distributors o Role: Sales to providers, logistics, wareh
Slide 26: Lumos Future Products
Lumos Future Products Women’s Sexual Health - $10B For personal use only 1-2 DAYS Prevalence Clinical Need POC Diagnostic Opportunity Affects 30%-40% of women globally. Multiple infectious organisms. Rapid & accurate testing close to the >10M heath care visits annually in the US Similar symptoms / h
Slide 27: Women's Sexual Health – The Opportunity
Women’s Sexual Health – The Opportunity IN CLINIC TESTING EXTERNAL LAB TESTING For personal use only Physical Exam Microscopic Exam Pathogen Testing Pathogen Testing 1-5 DAYS Practice Current Majority of clinics do not have in Instead, clinics send out testing to Lumos Women’s Sexual Health POC test
Slide 28: Lumos Product Roadmap | Women's Sexual Health
Lumos Product Roadmap | Women’s Sexual Health CURRENT - DISTRIBUTION FUTURE - LUMOS POC PRODUCTS GYN CLINIConly Revenue & Market Learning Pathogen Detection | Visual & Reader Interpretation URGENT CARE For personal use & Lumos – As a Distributer Lumos Products – Visual Read Lumos Products on Lumos R
Slide 29: Commercial Services Division
For personal use only Commercial Services Division © Lumos Diagnostics . All rights reserved. 27
Slide 30: Commercial Services Capabilities
Commercial Services Capabilities For personal use only Lumos offers the full range of in-house expertise required to deliver a complete, commercially ready solution DEVELOPMENT & MANUFACTURING PLATFORM TECHNOLOGIES ASSAY READERS EMR & CONNECTIVITIY © Lumos Diagnostics . All rights reserved. 28
Slide 31: Hologic - Strategic Partnership
Hologic - Strategic Partnership Fetal Fibronectin (fFN)1 Historic relationship with Lumos <> Hologic – For personal use only fFN is a biomarker indicating a heightened risk working together at multiple levels of pre-term delivery and is the largest segment Two agreements signed in FY24 for the devel
Slide 32: Hologic - fFN Product Development Overview And Opportunity
Hologic - fFN Product Development Overview And Opportunity For personal use only Current test: Next generation test Hologic – the opportunity ahead Rapid fFN TLiQ concept (mock-up) Verification Clinical and validation study Manufacturing Second test development and IP © Lumos Diagnostics . All right
Slide 33: Aptatek Phenylketonuria (PKU) In-home Monitoring Device
Aptatek Phenylketonuria (PKU) In-home Monitoring Device • PKU affects 1 in 12,000 newborns, leading to neurological For personal use only complications if un-checked • Lumos secures follow-on contract to move PKU in-home monitoring device to next stage of clinical development and commercial readines
Slide 34: Key Priorities
Key Priorities For personal use only FDA decision on the CLIA Implement agreement with Initiate FebriDx pediatric Deliver on Hologic fFN Progress to formal product waiver for FebriDx® is PHASE Scientific, advance study in October – fully development milestones - development on the first expected bet
Slide 35: Investor Briefing
For personal use only Lumos Diagnostics Holdings Limited Investor Briefing www.lumosdiagnostics.com © Lumos Diagnostics . All rights reserved. 33
Lumos Diagnostics Holdings — FY2025 Earnings Presentation on 6ix